This Week’s Biopharma News: EU Clears First Pertuzumab Biosimilar - Summary - MDSpire
Clinical Guidelines

This Week’s Biopharma News: EU Clears First Pertuzumab Biosimilar

Plus: NICE backs rozanolixizumab for uncontrolled gMG, Genexine reports SOX2 degrader data, and BeOne secures option on Huahui trispecific antibody

  • May 5, 2026

  • 5 min

Share

The European Commission has approved POHERDY, the first biosimilar for pertuzumab, which treats HER2-positive breast cancer, affirming its efficacy and safety for all indications of Roche's PERJETA. Concurrently, Genexine's GX-BP1 shows promising preclinical activity in targeting SOX2 for resistant cancers. NICE recommends rozanolixizumab for adults with uncontrolled generalized myasthenia gravis in England. Additionally, new bioprocessing labs and certifications are enhancing biopharmaceutical production capabilities across Asia.

Original Source(s)

This Week’s Biopharma News: EU Clears First Pertuzumab Biosimilar

  • May 5, 2026

Related Content

COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings

Patients diagnosed with metastatic breast cancer and non–small cell lung cancer had longer survival compared to national benchmarks when treated in independent community oncology practices, according ...

Zoldonrasib in Patients With <em>KRAS</em> G12D–Mutant NSCLC Previously Treated With Chemoimmunotherapy

The investigational KRAS G12D inhibitor zoldonrasib had a favorable safety profile and induced antitumor activity in some patients with KRAS G12D–mutated non–small cell lung cancer (NSCLC) who were pr...

Early-Onset ICI-Related Myocarditis Linked to Increased Mortality

Early-onset of immune checkpoint inhibitor (ICI)-related myocarditis was associated with an increased risk for myocarditis fatality, according to the results of a study presented at the American Assoc...